Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVID

Tevogen Bio Holdings Inc. (Nasdaq: TVGN) reported on September 23, 2025, that emerging research suggests a link between persistent viral reservoirs and Long COVID. This condition affects an estimated 20 million Americans and has been identified as an area of unmet medical need. Peer-reviewed studies indicate that residual SARS-CoV-2 proteins and RNA can remain in individuals for extended periods following acute infection, contributing to chronic immune inflammation and dysfunction associated with Long COVID symptoms. These findings support the exploration of new treatment methods aimed at eliminating residual viruses.

TVGN 489, Tevogen’s investigational precision T cell therapy developed from its ExacTcell™ platform, was designed to target multiple SARS-CoV-2 proteins rather than focusing solely on the Spike protein. In a proof-of-concept clinical trial, TVGN 489 demonstrated efficacy in reducing viral loads in participants, with T cells persisting for at least six months without interfering with patients’ immune responses. The company anticipates that TVGN 489 could provide a sustainable immune response against lingering SARS-CoV-2 fragments, addressing Long COVID treatment needs.

Tevogen is currently preparing for clinical manufacturing of TVGN 489 as further research continues to evaluate its potential effectiveness in restoring immune balance in patients suffering from Long COVID.